Faculty

Associate Professor Hirotomo Yamanashi

Speciality / Research theme / Keywords
General Medicine, Clinical Infectious Disease
Frailty, Sarcopenia, Multimorbidity and chronic infectious diseases
Supervision
Masters ProgrammeDoctoral Programme

Qualifications

MD, PhD

Personal/work Web page addresses

http://www.mh.nagasaki-u.ac.jp/soshin/
http://www.tm.nagasaki-u.ac.jp/internal/

Affiliation(s)

Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences
Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University
Department of General Medicine/ Infectious Diseases, Nagasaki University Hospital

Background

  • 2021-Present
    Associate Professor of Department of General Medicine
  • 2018-2021
    Senior lecturer of Department of General Medicine
    (Japan Disaster Relief Infectious Diseases Response Team in 2019)
  • 2013-2018
    Assistant professor of Department of Island and Community Medicine
    (Médecins Sans Frontières in 2016, 2017)
  • 2012-2013
    Staff doctor of Department of Infectious Diseases, Nagasaki University Hospital
  • 2011-2012
    Director of Ohi Kyodo Clinic
  • 2008-2011
    Senior Resident of Centre for Family Medicine Development Tokyo
  • 2006-2008
    Junior Doctor of Yokosuka Uwamachi General Hospital

Teaching

Giving lectures (General Medicine, Infectious diseases, and Community Health) in TMGH, Nagasaki University Graduate School of Biomedical Sciences and Nagasaki University Hospital.
Supervisor of Joint Nagasaki-LSHTM PhD Programme.

Research

I have been studying epidemiological studies in Vietnam, India, and Japan, particularly on primary care, geriatric medicine, clinical infectious diseases. I have participated in Nagasaki Islands Study since 2014, which is a prospective cohort study aiming to investigate genetic susceptibility to atherosclerosis, cardiovascular diseases, rheumatoid arthritis, and frail & sarcopenia. I am also engaged in international study collaborating with the Andhra Pradesh Children and Parents Study (PI: Professor Sanjay Kinra, LSHTM).

The country/countries where you work currently

Goto City, Nagasaki, Japan/ Hyderabad, India

Five MOST IMPORTANT/INTERESTING recent publications

  1. Yamanashi H, Nobusue K, Nonaka F, Honda Y, Shimizu Y, Kawashiri SY, Izumida M, Kubo Y, Tamai M, Nagata Y, Yanagihara K, Kulkarni B, Kinra S, Kawakami A, Maeda T. Human T-cell lymphotropic virus type-1 infection associated with sarcopenia: community-based cross-sectional study in Goto, Japan. Aging (Albany NY). 2020 Jul 24;12(15):15504-15513.
  2. Yamanashi H, Nobusue K, Nonaka F, Honda Y, Shimizu Y, Akabame S, Sugimoto T, Nagata Y, Maeda T. The role of mental disease on the association between multimorbidity and medical expenditure. Fam Pract. 2020 Sep 5;37(4):453-458. doi: 10.1093/fampra/cmaa015. PMID: 32086514
  3. Yamanashi H, Nagaoki K, Kanbara S, Shimizu Y, Murase K, Tsujino A, Maeda T. Relationships of handgrip strength with the presence of cerebral microbleeds and platelet count in older Japanese adults. Oncotarget. 2020 May 12;11(19):1705-1713. doi: 10.18632/oncotarget.27573. PMID: 32477460
  4. Yamanashi H, Kulkarni B, Edwards T, Kinra S, Koyamatsu J, Nagayoshi M, Shimizu Y, Maeda T, Cox SE. Association between atherosclerosis and handgrip strength in non-hypertensive populations in India and Japan. Geriatr Gerontol Int. 2018 Jul;18(7):1071-1078. doi: 10.1111/ggi.13312. PMID: 29582539
  5. Yamanashi H, Koyamatsu J, Nagayoshi M, Shimizu Y, Kawashiri SY, Kondo H, Fukui S, Tamai M, Sato S, Yanagihara K, Kawakami A, Maeda T. Human T-cell leukemia virus-1 infection is associated with atherosclerosis as measured by carotid intima-media thickness in Japanese community-dwelling older people. Clinical Infectious Diseases. 2018 Jul 2;67(2):291-294. doi: 10.1093/cid/ciy168. PMID: 29529133

Message

Emerging problems in the super-aged society is age-related functional decline, such as frailty, sarcopenia, and multimorbidity. I am keen to know how we can describe age-related functional decline in each community, and how we can respond to these issues globally in aspects of both clinical medicine and public health.

PAGE TOP